Shattuck Labs presents two UEG posters: what they mean for Shattuck Labs stock
Published on 10/21/2026 at 04:56 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSClinical milestones and reporting dates
- Shattuck Labs announced two UEG Week poster presentations on October 13, 2026.
- UBS initiated coverage with a USD 17.00 target on October 11, 2026.
- Shattuck Labs stock last stood at EUR 5.07 in Frankfurt on October 20, 2026.
- Third-quarter 2026 earnings are scheduled for November 10, 2026.
Shattuck Labs (ISIN US82024L1035) announced two poster presentations for United European Gastroenterology Week on October 13, 2026. MarketScreener reported that the presentations covered the bispecific antibody SL-846 and research into TL1A immune complexes.
What the posters mean for development
The company scheduled a moderated SL-846 poster for October 19, 2026, and an ePoster available throughout October 17 to October 20, 2026. The scientific program gives investors two concrete markers for Shattuck's DR3 research platform, while the lead candidate SL-325 remains the central clinical asset.
Markets Insider reported on October 1, 2026, that Shattuck planned a Phase 2 hidradenitis suppurativa trial for SL-325, designed to enroll approximately 150 patients. The study's Week 16 data are expected in the first half of 2028.
Three milestones since October 1
On October 1, 2026, Shattuck outlined the approximately 150-patient Phase 2 study. On October 11, 2026, UBS initiated coverage with a Buy rating and a USD 17.00 price target, according to Markets Insider. On October 13, 2026, the company announced two UEG Week poster presentations.
When are the next results due?
Barrons lists November 10, 2026, for third-quarter 2026 earnings and March 16, 2027, for fiscal-year 2026 earnings. Those dates give the clinical story a defined financial checkpoint.
Last Frankfurt indication
The last available euro price stood at EUR 5.07 in Frankfurt on October 20, 2026 at 8:15 p.m. CEST. Shattuck Labs had a market capitalization of USD 586.1 million and a 52-week range of USD 1.72 to USD 8.33 as of October 20, 2026.
Shattuck Labs stock facts
- Company: Shattuck Labs, Inc.
- ISIN: US82024L1035
- Ticker: STTK
- Primary exchange: Nasdaq
- Market capitalization: USD 586.1 million (as of October 20, 2026)
- 52-week range: USD 1.72-8.33 (as of October 20, 2026)
- Sector / Industry: Healthcare / Biotechnology
- Next earnings date: November 10, 2026
Market context: Market report S&P 500.
